Andrew R. Conery

2.7k total citations · 2 hit papers
16 papers, 1.9k citations indexed

About

Andrew R. Conery is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Andrew R. Conery has authored 16 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 6 papers in Hematology and 3 papers in Oncology. Recurrent topics in Andrew R. Conery's work include Protein Degradation and Inhibitors (8 papers), Multiple Myeloma Research and Treatments (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Andrew R. Conery is often cited by papers focused on Protein Degradation and Inhibitors (8 papers), Multiple Myeloma Research and Treatments (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Andrew R. Conery collaborates with scholars based in United States, United Kingdom and China. Andrew R. Conery's co-authors include Robert J. Sims, Barbara M. Bryant, Jennifer A. Mertz, Péter Sandy, Louise Bergeron, Srividya Balasubramanian, Deanna A. Mele, Andrea G. Cochran, Kunxin Luo and Tien C. Ko and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Genes & Development and PLoS ONE.

In The Last Decade

Andrew R. Conery

15 papers receiving 1.9k citations

Hit Papers

Targeting MYC dependence in cancer by inhibiting BET brom... 2011 2026 2016 2021 2011 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting MYC dependence in cancer by inhibiting BET bromodomains
    2011 876 citations Jennifer A. Mertz, Andrew R. Conery et al. Proceedings of the National Academy of Sciences profile →
  2. Bromodomains: a new target class for drug development
    2019 320 citations Andrea G. Cochran, Andrew R. Conery et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew R. Conery United States 11 1.7k 508 421 125 110 16 1.9k
Jessica Schmidt United States 14 1.4k 0.8× 1.0k 2.0× 477 1.1× 114 0.9× 132 1.2× 22 1.6k
Galinos Fanourakis Greece 15 1.6k 0.9× 816 1.6× 745 1.8× 243 1.9× 137 1.2× 27 2.0k
Michaël Sébag Canada 23 1.0k 0.6× 801 1.6× 766 1.8× 83 0.7× 199 1.8× 115 1.8k
Margaret Nieborowska-Skorska United States 23 1.1k 0.6× 1.2k 2.3× 478 1.1× 112 0.9× 140 1.3× 54 2.1k
William Senapedis United States 29 1.6k 1.0× 366 0.7× 661 1.6× 202 1.6× 129 1.2× 79 2.1k
Lara Tickenbrock Germany 18 1.0k 0.6× 715 1.4× 229 0.5× 138 1.1× 82 0.7× 28 1.5k
Yoko Ueno Japan 13 901 0.5× 268 0.5× 377 0.9× 123 1.0× 150 1.4× 19 1.4k
Yosuke Minami Japan 22 802 0.5× 812 1.6× 395 0.9× 148 1.2× 157 1.4× 103 1.6k
Mohammad Azam United States 18 694 0.4× 856 1.7× 318 0.8× 116 0.9× 98 0.9× 36 1.6k
Meaghan Wall Australia 23 983 0.6× 266 0.5× 330 0.8× 166 1.3× 232 2.1× 57 1.6k

Countries citing papers authored by Andrew R. Conery

Since Specialization
Citations

This map shows the geographic impact of Andrew R. Conery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew R. Conery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew R. Conery more than expected).

Fields of papers citing papers by Andrew R. Conery

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew R. Conery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew R. Conery. The network helps show where Andrew R. Conery may publish in the future.

Co-authorship network of co-authors of Andrew R. Conery

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew R. Conery. A scholar is included among the top collaborators of Andrew R. Conery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew R. Conery. Andrew R. Conery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Bommi‐Reddy, Archana, Esteban Terzo, Michael J. Steinbaugh, et al.. (2022). CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells. PLoS ONE. 17(3). e0262378–e0262378. 10 indexed citations
2.
Conery, Andrew R., Jennifer L. Rocnik, & Patrick Trojer. (2021). Small molecule targeting of chromatin writers in cancer. Nature Chemical Biology. 18(2). 124–133. 26 indexed citations
3.
Zhao, Feng, Patricia J. Keller, Jennifer A. Mertz, et al.. (2021). Abstract 2126: Therapeutic potential of CPI-0209. Cancer Research. 81(13_Supplement). 2126–2126. 1 indexed citations
4.
Cochran, Andrea G., Andrew R. Conery, & Robert J. Sims. (2019). Bromodomains: a new target class for drug development. Nature Reviews Drug Discovery. 18(8). 609–628. 320 indexed citations breakdown →
5.
Bommi‐Reddy, Archana, Esteban Terzo, Florence Poy, et al.. (2019). Abstract 4722: Efficacy of a novel EP300/CBP histone acetyltransferase inhibitor in hormone responsive breast cancer. 4722–4722. 1 indexed citations
6.
Bommi‐Reddy, Archana, Jonathan E. Wilson, Esteban Terzo, et al.. (2019). Abstract 4722: Efficacy of a novel EP300/CBP histone acetyltransferase inhibitor in hormone responsive breast cancer. Cancer Research. 79(13_Supplement). 4722–4722. 2 indexed citations
7.
Conery, Andrew R., Richard C. Centore, Archana Bommi‐Reddy, et al.. (2016). Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response. Cancer Research. 76(6). 1313–1319. 23 indexed citations
8.
Conery, Andrew R., Richard C. Centore, Adrianne Neiss, et al.. (2016). Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. eLife. 5. 84 indexed citations
9.
Keller, Patricia J., Andrew R. Conery, Richard C. Centore, et al.. (2016). Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Cancer Research. 76(14_Supplement). 4749–4749.
10.
Huang, Yinshi, Sabikun Nahar, Maite G. Fernández‐Barrena, et al.. (2016). Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Clinical Cancer Research. 22(16). 4259–4270. 40 indexed citations
11.
Mertz, Jennifer A., Andrew R. Conery, Barbara M. Bryant, et al.. (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences. 108(40). 16669–16674. 876 indexed citations breakdown →
12.
Tschöp, Katrin, Andrew R. Conery, Larisa Litovchick, et al.. (2011). A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes & Development. 25(8). 814–830. 97 indexed citations
13.
Conery, Andrew R. & Ed Harlow. (2010). High-throughput screens in diploid cells identify factors that contribute to the acquisition of chromosomal instability. Proceedings of the National Academy of Sciences. 107(35). 15455–15460. 15 indexed citations
14.
Conery, Andrew R., Sanja Sever, & Ed Harlow. (2010). Nucleoside diphosphate kinase Nm23-H1 regulates chromosomal stability by activating the GTPase dynamin during cytokinesis. Proceedings of the National Academy of Sciences. 107(35). 15461–15466. 29 indexed citations
15.
Pearlberg, Joseph, Sébastien Degot, Wilson O. Endege, et al.. (2005). Screens Using RNAi and cDNA Expression as Surrogates for Genetics in Mammalian Tissue Culture Cells. Cold Spring Harbor Symposia on Quantitative Biology. 70(0). 449–459. 22 indexed citations
16.
Conery, Andrew R., Yanna Cao, E. Aubrey Thompson, et al.. (2004). Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis. Nature Cell Biology. 6(4). 366–372. 338 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Schmidt Breakdown of academic impact, for papers by Galinos Fanourakis Breakdown of academic impact, for papers by Michaël Sébag Breakdown of academic impact, for papers by Margaret Nieborowska-Skorska Breakdown of academic impact, for papers by William Senapedis Breakdown of academic impact, for papers by Lara Tickenbrock Breakdown of academic impact, for papers by Yoko Ueno Breakdown of academic impact, for papers by Yosuke Minami Breakdown of academic impact, for papers by Mohammad Azam Breakdown of academic impact, for papers by Meaghan Wall
Rankless by CCL
2026